bluuebunny/crossref_metadata_2025_split huggingface dataset:
Charged Higgs induced 5 and 6 lepton signatures from heavy neutrinos at the LHC
Authors: Das Arindam , Kanemura Shinya , Sanyal Prasenjit 
Published: June 2023

AbstractWe propose an anomaly free gauged U(1) extension of the SM where three right handed heavy neutrinos, being charged under the general U(1) gauge group, are introduced to explain the origin of the tiny neutrino mass through the seesaw mechanism after the general U(1) symmetry is broken. Due to the breaking of the general U(1) symmetry a neutral beyond the standard model gauge boson $$Z^\prime $$

Z
′

acquires mass. There are two Higgs doublets in this model where one interacts with the SM fermions and the other one interacts with the right handed heavy neutrinos and charged leptons. The charged multiplet of the second Higgs can completely decay into the heavy neutrinos and charged lepton in the neutrinophilic limit of the model parameters. The charged Higgs pair production can be influenced due to presence of the $$Z^\prime $$

Z
′

boson at the High Luminosity LHC (HL-LHC) in addition to the neutral SM gauge bosons. The pair produced charged Higgs bosons decay into SM charged leptons and heavy neutrinos. Following the leading decay modes of the heavy neutrinos into charged leptons and W boson we study the 5 and 6 lepton final states after the leptonic and hadronic decay of the W bosons considering solely muons and electrons in the final state. Combining the electron and muon final states we estimate the significance of the 5 and 6 charged lepton processes in the $$m_{H^\pm }-m_N$$

m

H
±

-

m
N

plane for different benchmark points of $$m_{Z^\prime }$$

m

Z
′

. It is found that the 5 (6) charged lepton processes could be probed at the High Luminosity LHC (HL-LHC) with at least 5 (3) $$\sigma $$
σ
significance and there are parameter regions where the significance could be larger.
A note on Rivin’s interpretation of McShane’s identity as identities for closed geodesics with one self-intersection
Authors: Lei Da , Zhang Ying 
Published: June 2023

Rivin interpreted McShane’s identity as an identity for closed geodesics with one self-intersection on a one-cusped hyperbolic torus (cf. [I. Rivin, Geodesics with one self-intersection, and other stories, Adv. Math. 231 (2012) 2391–2412, Theorem 3.2]). In this note we point out that only those geodesics of non-hyperelliptic type are included in the interpreted identity, while those of hyperelliptic type are missing, and we give the desired identity for the closed geodesics with one self-intersection of hyperelliptic type. We also remark that the interpretation in [I. Rivin, Geodesics with one self-intersection, and other stories, Adv. Math. 231 (2012) 2391–2412, Theorem 3.7] of generalized McShane’s identity for a one-coned hyperbolic torus with cone angle [Formula: see text] is only partly valid because closed curves with one minimal self-intersection of non-hyperelliptic type are realizable as closed geodesics on the torus if and only if [Formula: see text].
Application of Nanoprecipitation Technique to Develop Poloxamer-407 Facilitated Solid Lipid Nanoparticles for the Controlled Delivery of Tacrolimus
Authors: Zaman Muhammad , Iqbal Asma , Sarwar Hafiz Shoaib , Butt Muhammad Hammad , Iqbal Muhammad Omer , Nissar Naveed , Mumtaz Asma , Nazeer Hafiza Yusra , Alshammari Abdulrahman , Riaz Muhammad Shahid 
Published: June 2023

Currently, the solid lipid nanoparticles (SLNs) are utilized as a novel approach for the controlled drug delivery system (CDDS). Tacrolimus (TCM), a lipophilic drug, can easily be encapsulated in the hydrophobic core of these SLNs using nanoprecipitation technique. The current aim was to develop the controlled release Poloxamer (PLX) facilitated TCM loaded SLNs (PLX/TCM-SLNs), followed by their physicochemical evaluations, including chemical compatibility, particle size, surface charge, surface morphology, nature of SLNs, loading efficiency (LE), entrapment efficiency (EE), in vitro drug release studies, release kinetic modeling, and statistical evaluation. Here we also evaluate physicochemical properties of TCM and investigate solubility profile for improvement and dissolution rate of PLX/TCM-SLNs. PLX was used in the process as a polymer due to its low toxicity and weak immunogenic properties. The prepared formulation was characterized by scanning electron microscopy (SEM) images, and Fourier transform infrared spectroscopy (FTIR) has confirmed the compatibility of the selected ingredients, whereas particle size analysis showed that prepared PLX/TCM-SLNs were of nanosized (

120.6
±
9

nm) having zeta potential of −21.3 Mv. On the other hand, SEM had revealed the smooth and uniform surface of the particle, while X-ray diffraction (XRD) confirmed the uniform surface as crystalline structure of TCM in PLX/TCM-SLNs masked. A satisfactory level of EE (

94.5
±
2.74

%) has also been noticed. Furthermore, in vitro drug release studies have explored the controlled release of drug during 8 hours, following zero order release kinetics and diffusion type of release mechanism. Outcomes of the studies have advocated the successful preparation of SLNs, as controlled release PLX/TCM-SLNs have been prepared efficiently.
Abstract 25: Competing Endogenous RNA (ceRNA) Networks Implicated in Prostate Cancer Progression to Castration Resistance Identified Through Bioinformatics Analyses
Authors: Ledesma-Bazan Sabrina , Cascardo Florencia , Bizzotto Juan , Ruiz María Sol , Vazquez Elba , Gueron Geraldine , Cotignola Javier 
Published: June 2023

Abstract
Purpose: Long non-coding RNAs (lncRNAs) regulate several biochemical pathways and contribute to the pathophysiology of cancer. In previous analyses, we identified 27 lncRNAs whose expression respond to hormone therapy in prostate cancer patients. Furthermore, in castration-resistant prostate cancer (CRPC), their levels were restored to those observed in therapy-naïve primary tumors. Nevertheless, lncRNAs contribution in tumorigenesis is still not understood. Since one mechanism of action of lncRNAs is acting as sponges of miRNAs, our main goal was to identify lncRNA-miRNA-mRNA networks altered during prostate cancer progression.
Methods: We performed a bioinformatics-based analysis using public datasets comprising 40 primary prostate tumors (11 paired pre- and post-androgen deprivation therapy (ADT) and 29 pre-ADT) and 8 CRPC. We used miRNet (a miRNA-centric network visual analytics platform) to seek miRNAs that target both lncRNAs and mRNAs, and constructed ceRNA networks.
Results: We identified 105 mRNAs differentially expressed in both post- vs pre-ADT primary tumors and CRPC vs post-ADT. We found that PCGEM1 (lncRNA) expression correlates with ASPM (mRNA) expression (r=0.51, p=8.2E-13), and these two RNAs have target sequences for the binding of hsa-miR-506-3p and hsa-miR-124-3p. These results identified a possible PCGEM1-hsa-miR-506-3p/hsa-miR-124-3p-ASPM ceRNA involved in prostate cancer progression to castration resistance. Other ceRNAs identified included RAB3B mRNA (RAS oncogene family) and are: PCGEM1-hsa-miR-124-3p-RAB3B, LINC01087-hsa-miR-130a-3p-RAB3B, and LINC01671-hsa-miR-145-5p-RAB3B.
Conclusion: These results give new insights in ceRNA dysregulation in prostate cancer; and ultimately, they might help to identify new prognostic biomarkers for prostate cancer and new druggable targets for avoiding/delaying progression to CRPC.
Citation Format: Sabrina Ledesma-Bazan, Florencia Cascardo, Juan Bizzotto, María Sol Ruiz, Elba Vazquez, Geraldine Gueron, Javier Cotignola. Competing Endogenous RNA (ceRNA) Networks Implicated in Prostate Cancer Progression to Castration Resistance Identified Through Bioinformatics Analyses [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 25.
Abstract 26: Correlation of Childhood Cancer Mortality Trends and CureAll Metrics for 134 LMICs
Authors: Rice Hannah , Smith Emily , Cotache-Condor Cesia , Majaliwa Esther , Espinoza Pamela , Metcalf Madeline , Rice Henry 
Published: June 2023

Abstract
Purpose: Disparities in cancer outcomes still remain in low-and-middle income countries (LMICs), where less than 30% of children living with cancer survive. In this context, the Global Initiative for Childhood Cancer has set the goal of achieving at least 60% survival for all countries by 2030. The aim of this study was to describe trends in childhood mortality rates for LMICs over time and evaluate their association with the health system metrics related to the WHO CureAll framework.
Methods: In this ecological study, childhood cancer was defined as all-cancers for the age group of 0-14 years old. Data were collected from public data sources including the Global Burden of Disease, WHO cancer profiles and World Bank. Descriptive analyses were performed to investigate mortality rate patterns over time (1990-2019). Exposure variables including density of hospital beds, density of CT scanners, density of MRI scanners, density of density of external beam radiotherapy, out-of-pocket expenditure, and universal health coverage index were evaluated against percent change of mortality of cancer rates (1990-2019). Smooth regression lines were used to visualize inflections points within income level groups.
Results: A total of 134 LMICs were included in this study. Overall, low-income countries had the major decrease in childhood mortality rates from 1900 to 2019. The top three countries with the highest decrease in rates were Malawi, Ethiopia, and Zambia deaths (-22.6 to -9.1/100,000 population). The top three countries with the highest increase in rates were Botswana, Burkina Faso, and Dominica (+1.2 to +1.8 deaths/100,000 population). The factors associated the most with changes in the childhood cancer mortality rates over time were improvements in infrastructure, such as increasing hospital beds and the availability of cancer treatments, increasing universal coverage, and decreasing out-of-pocket expenditures for healthcare costs.
Conclusion: An improved understanding of cancer mortality trends and their relation with health system variables in LMICs is important to monitor and evaluate progress in survival rates for children living with cancer in these countries. This study intends to provide insights on the use of health system metrics related to the WHO CureAll framework as priority interventions for childhood cancer in LMICs.
Citation Format: Hannah Rice, Emily Smith, Cesia Cotache-Condor, Esther Majaliwa, Pamela Espinoza, Madeline Metcalf, Henry Rice. Correlation of Childhood Cancer Mortality Trends and CureAll Metrics for 134 LMICs [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 26.
Abstract 37: Exploring the Impact of Metastatic Breast Cancer Support Group in Nigeria
Authors: Chidebe Runcie C.W. , Orji Mary-Gloria A. , Zitta-Nwosu Theodora , Banwo-Fatai Khadijat , Agha Agha A. , Esiaka Darlingtina K. , Orjiakor Tochukwu C. 
Published: June 2023

Abstract
Purpose: Over 70% of breast cancer patients in Nigeria present metastatic/advanced breast cancer (MBC). An estimated 90% of breast cancer deaths are a result of metastatic disease, either at diagnosis or recurrence. MBC is associated with a severe burden to the patient, family, healthcare delivery system and society at large. Women living with MBC face many challenges ranging from poor access to MBC information, untreated pain, frequent breakdown of radiotherapy machines and absence of peer support.
Methods: In this research, we set up the first metastatic breast cancer support group in Abuja. The group meet once every month on a face-to-face basis and also uses WhatsApp group for regular meaningful engagement. We explored the impact of the group on the patient’s quality of life (QoL) using a focused group discussion (FGD). Eighteen (18) patients participated in the two sessions of FGD. We also conducted a follow-up semi-structured interview with 8 MBC patients.
Results: Many of the patients report that the support group provides a culture of love and strength over their death anxiety, especially meeting other patients who have lived with MBC longer. They also report having found peer support on the online WhatsApp group.
Citation Format: Runcie C.W. Chidebe, Mary-Gloria A. Orji, Theodora Zitta-Nwosu, Khadijat Banwo-Fatai, Agha A. Agha, Darlingtina K. Esiaka, Tochukwu C. Orjiakor. Exploring the Impact of Metastatic Breast Cancer Support Group in Nigeria [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 37.
Abstract 4: A SEER Analysis of Demographic Factors Associated With Ceruminous Adenocarcinoma, 2000-2019
Authors: Hsia Beau , Keirns Darby , Silberstein Peter , Wu Xinxin 
Published: June 2023

Abstract
Purpose: Ceruminous adenocarcinoma (CA) is an uncommon malignancy that arises from the ceruminous glands located in the external auditory canal. Although rare, 25% of patients with CA die of the disease within 2 years of presentation. CA has a 10-year survival rate of 60% with radiation treatment and 30% without radiation treatment. The rarity of this tumor type, combined with a lack of published data, makes it difficult to fully understand its clinical characteristics and optimal management strategies. A study on its epidemiology could offer valuable insight into the diagnostic trend of the disease. The Surveillance Epidemiology and End Results (SEER) database was analyzed to determine the demographic factors in patients diagnosed with CA.
Methods: A retrospective cohort analysis utilizing the SEER database from 2000 to 2019 included patients with a confirmed diagnosis of CA (N=45). Cross-tabulation of the demographic factors (age, sex, race, marital status, and Hispanic origin) was analyzed by Pearson’s chi-squared test (p=0.05) and incidence trends were interpreted in regression analysis.
Results: There has been a downward trend in incidence rates of patients diagnosed with CA since 2007 (R2=0.139) with an average of 2.25 diagnoses per year. A total of 45 patients were identified in the database with a confirmed diagnosis of CA. The average age of diagnosis was 60.0 years (SD=15.4, range=26–88 years). The top primary site was the external ear (69%), followed by skin of the trunk (8.9%) and skin of the lower limb (6.7%). The majority of the patients were male (53%), non-Spanish-Hispanic-Latino (91%), and White (82%) followed by Black (8.9%), and Asian/Pacific Islanders (6.7%). More patients (40%) were married at the time of diagnosis than those who were widowed (13%), single (9%), or divorced (7%), with the rest having unknown marital status (31%). There were no statistically significant differences between the demographic factors and the primary site at which CA presents.
Conclusion: The majority of CA patients tend to be non-Hispanic White males with a declining number of cases each year. Further research is needed to better understand the impact of demographic factors on the diagnosis and overall survival of patients with CA, as well as the reason for the decreased incidence and possible underdiagnosis of the disease.
Citation Format: Beau Hsia, Darby Keirns, Peter Silberstein, Xinxin Wu. A SEER Analysis of Demographic Factors Associated With Ceruminous Adenocarcinoma, 2000-2019 [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 4.
Abstract 41: Global Oncology Projects at NCI-Designated Cancer Centers: A Focus on Implementation Science
Authors: Frank Allison , Garton Elise , Eldridge Linsey , Cira Mishka Kohli , Duncan Kalina 
Published: June 2023

Abstract
Purpose: Advancing global cancer research and control in low- and middle-income countries (LMICs) is a key priority for the U.S. National Cancer Institute (NCI) Center for Global Health (CGH). As a part of this work CGH supports a network of 71 NCI-Designated Cancer Centers in their international activities, and regularly surveys cancer centers to understand their global oncology related activities. For the 2021 survey, CGH asked cancer centers to indicate which of their global oncology projects focused on implementation science (IS), a CGH strategic priority that relates to the theme of ASGCR 2023.
Methods: CGH fielded an online survey from July 2021 through January 2022 to understand cancer centers’ non-NIH-funded global oncology programs, activities, and projects. Global oncology leads and principal investigators (PIs) were asked to report project details and areas of focus. Analysis was conducted in Microsoft Excel and Python. Comparable NIH-funded awards were sourced from NIH internal systems.
Results: 52 cancer centers reported details of 447 non-NIH funded global oncology projects, of which, 33 cancer centers reported 125 IS projects. IS projects covered all six Common Scientific Outline (CSO) codes, with the top code being Early Detection, Diagnosis, and Prognosis (86 projects). All coded project types were reported (research, capacity building/training, and clinical practice), with most projects categorized as research (96 projects). IS projects included collaborators from 48 countries, including 32 LMICs. These data were compared to fiscal year 2021 grants to cancer centers from the NIH Dissemination and Implementation Research (DIRH) program. While the DIRH program is not the only IS funding from NIH, only one DIRH grant to a cancer center included a foreign collaborator, suggesting that cancer centers are mostly using non-NIH funding for IS work.
Conclusion: A substantial proportion of cancer centers’ non-NIH funded global oncology work is focused on IS, and further analysis of these projects is warranted. CGH will use these and other results of this survey to inform research priorities and encourage collaboration between cancer centers and international partners. These data can be used by the global oncology community to further advance NCI-Designated Cancer Center-led work in IS.
Citation Format: Allison Frank, Elise Garton, Linsey Eldridge, Mishka Kohli Cira, Kalina Duncan. Global Oncology Projects at NCI-Designated Cancer Centers: A Focus on Implementation Science [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 41.
Abstract 75: Swahili Translation and Cultural Adaptation of the Cancer Stigma Scale (CASS) for Use in the Non-Patient Population in Tanzania
Authors: Schroeder Kristin , Mayolwa Kashinje , Posani Suhana , Mtenga Norbert , Pham Hong , Meck Zakia , Sued Hillary , Karia Francis , Sanga Erica 
Published: June 2023

Abstract
Purpose: The Cataldo Cancer Stigma Scale (CASS) was developed to measure patient experienced stigma, and further modified for use in non-patient communities. The aim of this study was to adapt a Swahili language version of the CASS for use in the Tanzanian non-patient community, to identify the current level of stigma towards children with cancerand create a measure to monitor changes in perceptions following future community based interventions.
Methods: An expert group of medical providers, community advisors and social scientists reviewed the 26 original statements in the CASS survey to determine relevancy in the Tanzanian context or Swahili language. A team of six native Swahili speakers was used to translate, back translate, reconcile, and adjudicate differences during the translation process. The final forward translation had in independent review by three bilingual translation experts to select the most appropriate translation for each item. The translated items were further refined using concurrent cognitive interviewing. Each round of interviews included five non-patient community members in the Mwanza region of Tanzania, and continued until &gt;80% concordance reached.
Results: Three rounds of revisions were completed with 15 respondents in total. A total of 62% of questions (22/36) were fully comprehended after the initial evaluation. Additional reviews included grammar and specific Swahili word selection changes to clarify the item’s meaning. After three rounds of interviews, all questions obtained at least 80% comprehension with no further revisions required. The final survey included 23 core questions and 10 alternate questions to target community beliefs identified during qualitative interviews. These included personal responsibility items evaluating the perception that cancer is caused by witchcraft and that cancer in children is a form of ancestral punishment.
Conclusions: A Swahili adapted CASS for use in the non-patient community had good comprehension among rural and urban members of the Mwanza community. The survey will require additional quantitative validation to determine both the structural validity and reliability of the constructs. This adapted tool will allow for a meaningful intervention response evaluation that can be used in cancer stigma research throughout East Africa.
Citation Format: Kristin Schroeder, Kashinje Mayolwa, Suhana Posani, Norbert Mtenga, Hong Pham, Zakia Meck, Hillary Sued, Francis Karia, Erica Sanga. Swahili Translation and Cultural Adaptation of the Cancer Stigma Scale (CASS) for Use in the Non-Patient Population in Tanzania [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 75.
Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Authors: Li Xiaoyu , Li Jingjing , Zheng Yue , Lee Sandra J. , Zhou Jun , Giobbie-Hurder Anita , Butterfield Lisa H. , Dranoff Glenn , Hodi F. Stephen 
Published: June 2023

Abstract
With the successful development of immune checkpoint blockade, there remains the continued need to improve efficacy and decrease toxicities. The addition of granulocyte–macrophage colony-stimulating factor (GM-CSF) to ipilimumab has previously demonstrated both an improvement in efficacy and decrease in the incidence of high-grade adverse events. ICOS+CD4+ or ICOS+CD8+ peripheral blood T cells are significantly greater in the patients treated with ipilimumab plus GM-CSF than in the patients treated with ipilimumab alone. To better understand the effects of GM-CSF on inducible T-cell costimulator (ICOS) and clinical outcomes, the relative roles of identified soluble ICOS and membrane-bound ICOS were evaluated. The ICOS splice variant was secreted and found to have immunologic suppressive effects. Changes in soluble ICOS splice variant levels in treated patients correlated with clinical outcomes. GM-CSF enhanced membrane-bound ICOS in an IL12-dependent manner but did not increase soluble ICOS levels. Whereas soluble ICOS plays a role in immune suppression, GM-CSF efficacy involves increasing membrane-bound ICOS and induction of dendritic cell development. Thus, soluble ICOS splice variants may be used as a biomarker for GM-CSF and immune checkpoint blockade–based therapies.